medigraphic.com
Instituto Nacional de Salud Pública

2003, Número S3

<< Anterior Siguiente >>

salud publica mex 2003; 45 (S3)


Serología para el virus del papiloma humano

Coursaget P

Idioma: Ingles.
Referencias bibliográficas: 81
Paginas: 361-366
Archivo PDF: 145.15 Kb.


RESUMEN

Las limitaciones para la utilización de la serología para el estudio del virus del papiloma humano con fines clínicos están asociadas con la gran variedad de subtipos humanos, con las reacciones cruzadas que existen entre diversos genotipos, la diversidad de lesiones precursoras de cáncer y con los sitios blancos de infección. Asimismo, la expresión del virus del papiloma humano en las capas superficiales del epitelio dan origen a una débil presentación de células inmunocompetentes de antígenos virales, lo cual origina una elevación de la respuesta serológica. Distintos esfuerzos se han realizado en décadas previas para desarrollar ensayos serológicos más específicos y sensibles. En muchas investigaciones se ha utilizado una fusión de proteínas y péptidos sintéticos que tienen como principal limitación su escasa sensibilidad y especificidad. Sólo en los últimos años, y principalmente debido al arribo de partículas parecidas a este virus, tenemos disponibles ensayos más sensibles y específicos, ampliamente descritos en este artículo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Banks L, Matlashewski G, Pim D, Churcher M, Roberts C, Crawford L. Expression of human papillomavirus type 6 and type 16 capsid proteins in bacteria and their antigenic characterization. J Gen Virol 1987;68:3081-3089.

  2. Li CC, Shah KV, Seth A, Gilden RV. Identification of human papillomavirus type 6b open reading frame protein and corresponding antibodies in human sera. J Virol 1987;61:2684-2690.

  3. Cason J, Kambo PK, Best JM, McCance DJ. Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type 16 (HPV16) in sera from patients with cervical intraepithelial neoplasia and in children. Int J Cancer 1992;50:349-355.

  4. Rosales R, López-Contreras M, Cortés RR. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: Correlation with presence of papillomavirus DNA. J Med Virol 2001;65:736-744.

  5. Rocha-Zavaleta L, Jordan D, Pepper S, Corbitt G, Clarke F, Maitland NJ et al. Difference in serological IgA responses to recombinant baculovirusderived human papillomavirus E2 protein in the natural history of cervical neoplasia. Br J Cancer 1997;75:1144-1150.

  6. Müller M, Gissmann L, Cristiano R, Sun X, Frazer I, Jenson A et al. Papillomavirus capside binding and uptake by cells from differents tissues and species. J virol 1995;69:948-954.

  7. Dillner J. Serology of human papillomavirus. Cancer J 1997;8:264-269.

  8. Kanda T, Onza T, Zanma S, Yasugi T, Furuno A, Watanabe S et al. Independent association of antibodies against human papillomavirus type 16 E1/E4 and E7 proteins with cervical cancer. Virology 1992;190:724-732.

  9. Dillner J. Mapping of linear epitopes of human papillomavirus type 16: The E1, E2, E4, E6 and E7 open reading frames. Int J Cancer 1990;46:703-711.

  10. Mann VM, de Lao SL, Brenes M, Brinon LA, Rawis JA, Green M et al. Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls. Cancer Res 1990;50:7815-7819.

  11. Müller M, Viscidi RP, Sun Y, Guerrero E, Hill PM, Shah F et al. Antibodies to HPV-16 E6 and E7 proteins as masrkers for HPV-16 associated invasive cervical cancer. Virology 1992;187:508-514.

  12. Jochmus-Kudielka I, Schnider A, Braun R, Kimmig R, Koldovsky U, Schneweis KE et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: Correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989;81:1698-1704.

  13. Bleul C, Müller M, Frank R, Gausepohol U, Mgaya HN, Luane J et al. Human papillomavirus type 18 E6 and E7 antibodies in human sera: Increased anti-E7 prevalence in cervical cancer patients. J Clin Microbiol 191;29:1579-1588.

  14. Viscidi RP, Sun Y, Tsuzaki B, Bosch FX, Muñoz N, Shah KV. Serologic response in human papillomavirus-associated invasive cervical cancer. Int J Cancer 1993;55:780-784.

  15. Gaarenstroom KM, Kenter GG, Bonfrer JM, Korse CM, Galle MP, Hart AA et al. Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer. Cancer 1994;74:2307-2313.

  16. Hamsikova E, Novack J, Hofmannova V, Muñoz N, Bosch FX, De Sanjosé S et al. Presence of antibodies to seven human papillomavirus type-16-derived peptides in cervical cancer patients and healthy controls. J Infect Dis 1994;170:1424-1431.

  17. Nindl I, Zumbach K, Pawlita M, Teller K, Scheinder A, Durst M. Absence of antibody against human papillomavirus type 1 6 E6 and E7 in patients with cervical cancer is independent of sequence variations. J Infect Dis 2000;181:1764-1767.

  18. Meschede W, Zumbach K, Braspenning J, Scheffner M, Benítez-Bribiesca L et al. Antibodies against early proteins of human papillomavirus as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998;36:475-480.

  19. Silins I, Avall-Ludqvist E, Tadesse A, Jansen KU, Stgendahl U, Lenner P et al. Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol Oncol 2000;85:333-338.

  20. Steele JC, Gallimore PH. Humoral assays of human sera to disrupted and non-disrupted epitopes of papillomavirus type 1. Virology 1990;174:388-398.

  21. Viac J, Chomel JJ, Chardonnet Y, Aymard M. Incidence of antibodies to human papillomavirus type 1 in patients with cutaneous and mucosal papillomavirus. J Med Virol 1990; 21:18-21.

  22. Schiller JT, Roden RB. Papillomavirus-like particles. Papillomavirus Rep 1995;6:121-128.

  23. Schiller JT, Lowry DR. Papillomavirus-like particles and HPV vaccine development. Cancer Biol 1996;7:373-382.

  24. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L et al. Efficient self-assembly of human papillomavirus type 16 L1 and L2 into virus like particles. J Virol 1993;67:6929-6936.

  25. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by the L1 and L2 capsid proteins. J Virol 1993;67:315-322.

  26. Hagansee ME, Olson NH, Baker TS, Galloway DA. Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol 1994;68:4503-4505.

  27. Wang Z, Christensen N, Schilleer JT, Dillner J. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 1997;78:2209-2215.

  28. Bousarghin L, Combita-Rojas AL, Touze A, El Mehdaoui S, Sisarte PY, Bravo MM, et al. Detection of neutralizing antibodies against human papillomavirus (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol 2002;40:926-932.

  29. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type II recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994;75:2075-2079.

  30. Roden RBS, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996;70:3298-3301.

  31. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998;72:959-964.

  32. Giroglou T, Sapp M, Lane C, Fligge C, Christensen N, Streeck RE et al. Immunological analyses of human papillomavirus capside. Vaccine 2001;19:1783-1793.

  33. Combita AL, Bravo MM, Touze A, Orozco O, Coursaget P. Serologic response to human oncogenic papillomavirus types 16,18,31,33,39,58 and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 2002;97:796-803.

  34. Andersson-Ellestrom A, Dillner J, Hagmar B, Schiller J, Sapp M, Forssman L et al. Comparison of development of serum antibodies to HPV 16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 1996;23:234-238.

  35. Touzé A, de Sanjosé S, Cousaget P, Almirall MR, Palacio V, Meijer CJLM et al. Prevalence of anti-human papillomavirus types 16, 18, 31 and 58 virus-like particles in women of the general population and in prostitutes. J Clin Microbiol 2001;39:4344-4348.

  36. Shin HR, Lee DH, Herrero R, Smith J, Vaccarella S, Hong SH et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003;103:413-414.

  37. Af Geijerrstam V, Eklund C, Wang Z, Sapp M, Schiller JT, Dillner J. A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer 1999;80:2489-2493.

  38. Cheng G, Icenogle JP, Kirnbauer R, Hubbert NL, St Louis ME, Han C, Svare EI et al. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis 1995;172:1548-1587.

  39. Touzé A, El Mehdaoui S, Sizaret PY, Mougin C, Muñoz N, Coursaget P. The L1 major capsid protein of human papillomavirus type 16 variants affects the yield of virus-like particle produced in an insect cells expression system. J Clin Microbiol 1998;36:2046-2051.

  40. Pastrana DV, Vass WC, Lowy DR, Schiller JT. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV 16. Virology 2001;279:361-369.

  41. Heino P, Skyldberg B, Lehtinen M, Rantala I, Hagmar H, Kreider JW et al. Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. J Gen Virol 1995;76:1141-1153.

  42. Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL. Human papillomavirus type 11 recombinant L1 capsomeres induce virusneutralizing antibodies. J Virol 1998;72:6151-6154.

  43. Touzé A, Dupuy C, Mahé D, Siaret PY, Coursaget P. Production of recombinant virus-like particles from human papillomavirus type 6 and 11, and study of serological reactivities between HPV 6, 11,16 and 45 by ELISA: Implications for papillomavirus prevention and detection. FEMS Microbiol Lett 1998;160:111-118.

  44. Giroglou T, Florin L, Schäfer F, Streeck RE, Sapp M. Human Papillomavirus infection requires cell surface heparan sulfate. J Virol 2001;75:1565-1570.

  45. Christensen ND, Kirnbauer R, Schiller JT, Chim SJ, Schlegel R, Jenson AB et al. Human papillomavirus types 6 a 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 1994;205:329-335.

  46. Heim K, Christensen ND, Hoepfl R. Serum IgG, IgM, and IgA reactivity to human papillomavirus type 11 and 6 virus-like particles in different gynecologic patient groups. J Infect Dis 1995;172:395-402.

  47. Ludmerer SW, Benincasa D, Mark GE. Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type II. J Virol 1996;70:4791-4794.

  48. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. Monoclonal antibodies to HPV-6 L1 virus like particle identify conformational and linear neutralizing epitope on HPV-11 in addition to type specific epitope on HPV-6. Virology 1996;224:477-486.

  49. Rose RC, Bonnez W, Da Rin C, McCance DJ, Reichman RC. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol 1994b;75:2445-2449.

  50. Nonnenmacher B, Hubbert NL, Kirnbauer R, Shah KV, Muñoz N, Bosch FX et al. Serologic response to human papillomavirus type 16 (HPV 16) virus like particles in HPV 16 DNA positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995;172:19-24.

  51. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-936.

  52. Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauert R et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case control study. Br Med J 1996;312:537-539.

  53. de Gruijl TD, Bontkes H, Walboomers J, Schiller J, Stukart, Groot B et al. Immunoglobulin G responses against human papillomavirus type 16 viruslike particles in a prospective nonintervention cohort study of women with cervical intraepitheliel neoplasia. J Natl Cancer Inst 1997;89:630-638.

  54. Af Geijersstam V, Kibur M, Wang Z, Koskela P, Pukkala E, Schiller J et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998;177:1710-1714.

  55. Van Doornum G, Prins M, Andersson-Ellstrom A, Dillner J. Immunoglobulin A, G and M responses to L1 and L2 capsids of human papillomavirus type 6, 16, 11,18 and 33 L1 after newly acquired infection. Sex Transm Infect 1998;74:354-360.

  56. Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert NL, Kirnbauer R, Greer CE. Evaluation of sero-reactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995;172:1425-1430.

  57. Carter JJ, Galaway DA. Humoral immune response to human papillomavirus infection. Clin Dermatol 1997;15:249-259.

  58. Stanley M. Immune responses to human papillomaviruses. In: Sterling JC, Tyring SK, ed. Human papillomaviruses: Clinical and scientific advances. Arnold, Londres: 2001;38-49.

  59. Kirnbauer R, Hubbert NL,Wheeler C, Lowy DR, Schiller JT. A virus-like particle ELISA detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:498-498.

  60. Le Cann P, Touzé A, Enogat N, leboulleux D, Mougin C, Legrand MC et al. Detection of antibodies against the human papillomavirus type 16 virions by means of ELISA using recombinant HPV 16 L1 capsids produced by recombinant baculovirus. J Clin Microbiol 1995;33:1380-1382.

  61. Sasagawa T, Inoue M, Lehtinen M, Zang W, Gschmeissner SE, Hajibagheri MA et al. Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions. Clin Diagn Lab Immunol 1996;3:403-410.

  62. Wideroff L, Schiffman MH, Haderer P, Armstrong A, Greer CE, Manos MM. Seroreactivity to human papillomavirus type 16, 18, 31 and 45 VLP in a case control study of cervical squamous intraepithelial lesions. J Infect Dis 1999;180:1424-1428.

  63. Bontkes HJ, de Gruijl TD, Walboomers JM, Schiller JT, Dillner J, Helmerhorst TJ et al. Immune responses against human papillomavirus (HPV) type 16 virus –like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen virol 1999;80:409-417.

  64. Hisada M, van den Berg Bj, Stricler HD, Chrisrianson RE, Wright WE, Waters DJ et al. Prospective study of antibody to human papillomavirus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). Cancer Causes Control 2001;12:335-341.

  65. Wideroff L, Schiffman MH, Hoover R, Tarone RE, Nonnenmacher B, Hubbert N. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNApositive and negative women. J Infect Dis 1996;174:937-943.

  66. Eisemann C, Fisher SG, Gross G, Müller M, Gissmann L. Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups. J Gen Virol 1996;77:1799-1803.

  67. Carter JJ, Wipf GC, Hagaensee ME, McKnight B, Habel LA, Lee SK et al. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 1995;172:11-18.

  68. Marais DJ, Vardas E, Ramjee G, Allan B, Kay P, Rose RC et al. The impact of human immunodeficiency virus type 1 status on human papillomavirus (HPV) prevalence and HPV antibodies in serum and cervical secretions. J Infect Dis 2000;182:1239-1242.

  69. Petter A, Heim K, Guger M, Cisera-König, Christensen N, Sarcletti MM et al. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women. J Gen Virol 2000;81:701-708.

  70. Newton R, Bousarghin L, Ziegler J, Casabonne D, Beral V, Mbidde E et al. Human papillomaviruses and cancer in Uganda. Submitted.

  71. Kjaer SK, Chackerian B, van den Brule AJ, Avare EI, Paull G, Walbomers JM et al. High-risk human papillomavirus is sexually transmitted: Evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001;10:101-106.

  72. Dillner J, Kallings I, Brihmer C, Sikstrom B, Koskela P, Lehtinen M et al. Seropositivities to human papillomavirus types 16, 18 or 33 capsids and to chlamydia trachomanis are markers of sexual behavior. J Infect Dis 1996;173:1394-1398.

  73. Heino P, Eklund C, Fredriksson-Shanazarian V, Goldman S, Schiller JT, Dillner J. Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst 1995b;87:437-440.

  74. Bjorge T, Dillner J, Anttila T, Engeland A, Hakulinen T, Jellum E et al. Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. Br Med J 1997;315:646-649.

  75. Carter JJ, Madeleine MM, Shera K, Schwartz SM, Cushing-Haugen KL, Wipf GC et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001;61:1934-1940.

  76. Muñoz N. Human papillomavirus and cancer: The epidemiological evidence. J Clin Virol 2000;19:1-5.

  77. Olsen AO, Dillner J, Gjoen K, Sauer T, Orstavik I, Magnus P. A populationbased case-control study of human papillomavirus type 16 seropositivity and incident high-grade dysplasia of the uterine cervix. Int J Cancer 1996;68:415-419.

  78. Hildesheim A, Han CL, Brinton LA, Kurman RJ, Schiller JT. Human papillomavirus type 16 and risk of preinvasive vulvar cancer: Results from a seroepidemiological case-control study. Obstet Gynecol 1997;90:748-754.

  79. Hagensee ME, Slavinsky J 3rd, Gaffga CM, Suros J, Kissinger P, Martin DH. Seroprevalence of human papillomavirus type 16 in pregnant women. Obstet Gynecol 1999;94:653-658.

  80. Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001;92:2875-2884.

  81. Giovannelli L, Campisi G, Lama A, Giambalvo O, Osborn J, Margiotta V et al. Human papillomavirus DNA in oral mucosal lesions. J Infect Dis 2002;185:833-836.




2020     |     www.medigraphic.com